Browse studies

Find your next paid study

6 recruiting studies matching your filters

A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of Vosoritide in Infants and Young Children With Hypochondroplasia, Aged 0 to < 36 Months

The purpose of this study is to evaluate the safety and efficacy of daily administration of vosoritide in participants with HCH aged 0 to \< 36 months over a 5…

Hypochondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

BioMarin PharmaceuticalNCT07126262

Prospective Clinical Assessment Study in Children With Hypochondroplasia: ACCEL

This is a long-term, multicenter, non-interventional study of children ages 2.5 to \<17 years with hypochondroplasia (HCH).

Hypochondroplasia

Estimated

~$10 – $1,050

Actual pay is set by the research site.

QED Therapeutics, a BridgeBio companyNCT06410976

A Multicenter Multinational Observational Study of Children With Hypochondroplasia

This study will assess growth over time and the clinical course of HCH in children by collecting growth measurements and other variables of interest.

Hypochondroplasia

Estimated

~$10 – $1,050

Actual pay is set by the research site.

BioMarin PharmaceuticalNCT06212947

Phase 3

A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia

The purpose of this study is to evaluate the long-term safety and efficacy of daily doses of vosoritide in participants with HCH

Hypochondroplasia

Estimated

~$50 – $2,100

Actual pay is set by the research site.

BioMarin PharmaceuticalNCT07073014

Phase 2

A Phase 2/3, Multicenter, Open-Label Phase Followed by a Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children With Hypochondroplasia: ACCEL 2/3

ACCEL2/3 is a Phase 2/3 study. The purpose of the Phase 2 portion of the study (ACCEL2/3) is to evaluate the efficacy and safety of infigratinib in children wi…

Hypochondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

QED Therapeutics, a BridgeBio companyNCT06873035

Phase 2

Phase 2, Open-Label, Long-Term, Extension (OLE) Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Hypochondroplasia: ACCEL OLE

Phase 2, multicenter, OLE study to evaluate the long-term safety, tolerability, and efficacy of infigratinib, an FGFR (fibroblast growth factor receptor) 1-3-s…

Hypochondroplasia

Estimated

~$75 – $2,800

Actual pay is set by the research site.

QED Therapeutics, a BridgeBio companyNCT07393373